

1 **TITLE:** Prevalence and Outcomes Associated with Idarucizumab Administration in Trauma
2 Patients on Preinjury Dabigatran Therapy: Analyzing Clinical Utilization in 942 Patients from 74
3 Hospitals

4
5 **AUTHOR NAMES, ACADEMIC DEGREES, AND AFFILIATIONS:**

6 Rebecca L. Moore, PharmD: HCA Healthcare/University of Tennessee College of Pharmacy
7 PGY2 Residency Program, Clinical Services Group, HCA Healthcare, Nashville, TN 37203 ;
8 rebecca.moore2@hcahealthcare.com

9
10 Ransom J. Wyse, MPH: Center for Trauma and Acute Care Surgery Research, Clinical Services
11 Group, HCA Healthcare, Nashville, TN 37203 ; ransom.wyse@hcahealthcare.com ; ORCID #:
12 0000-0003-4558-1702

13
14 Justin Jacobs, MS: Center for Trauma and Acute Care Surgery Research, Clinical Services
15 Group, HCA Healthcare, Nashville, TN 37203 ; justin.jacobs@hcahealthcare.com ; ORCID #:
16 0000-0002-5621-5962

17
18 Samir M. Fakhry, MD: Center for Trauma and Acute Care Surgery Research, Clinical Services
19 Group, HCA Healthcare, Nashville, TN 37203 ; Samir.fakhry@hcahealthcare.com ; ORCID #:
20 0000-0002-6781-0863

21

22 Nina Y. Wilson, MSN: Center for Trauma and Acute Care Surgery Research, Clinical Services
23 Group, HCA Healthcare, Nashville, TN 37203 ; nina.yoes@hcahealthcare.com ; ORCID #:
24 0000-0002-2560-7779

25
26 Jeneva M. Garland, PharmD: Center for Trauma and Acute Care Surgery Research, Clinical
27 Services Group, HCA Healthcare, Nashville, TN 37203 ; jenny.garland@hcahealthcare.com ;
28 ORCID #: 0000-0003-4920-3020

29
30 **AUTHOR AFFILIATION:** This research was supported (in whole or in part) by HCA
31 Healthcare and/or an HCA Healthcare affiliated entity. The views expressed in this publication
32 represent those of the authors and do not necessarily represent the official views of HCA
33 Healthcare or any of its affiliated entities.

34
35 **MEETING PRESENTATION:** This work was presented as a poster presentation at the Annual
36 Midyear Clinical Meeting and Exhibition of the American Society of Health-System Pharmacists
37 in Las Vegas, Nevada, on December 7, 2022.

38
39 **SHORT TITLE:** Idarucizumab Administration in Trauma Patients

40
41 **CORRESPONDING AUTHOR:**

42 Samir M. Fakhry, MD FACS
43 Center for Trauma and Acute Care Surgery Research
44 HCA Healthcare, Clinical Services Group

45 2515 Park Plaza, Bldg 2-3W

46 Nashville, TN 37203

47 Mobile phone: 615-295-6844

48 Work phone: 615-344-5408

49 samir.fakhry@hcahealthcare.com

50

51 **MANUSCRIPT WORD COUNT: 3,447**

52 **ABSTRACT WORD COUNT: 345**

53

54 **ICMJE AUTHORSHIP CONTRIBUTIONS:**

55 **RLM:** Conceptualization, Methodology, Investigation, Writing - Original Draft, Writing -

56 Review & Editing, Supervision, Project Administration **RJW:** Methodology, Investigation,

57 Writing - Original Draft, Writing - Review & Editing, Project Administration **JJ:** Software,

58 Validation, Formal Analysis, Investigation, Data Curation, Writing - Original Draft, Writing -

59 Review & Editing, Visualization **SMF:** Conceptualization, Methodology, Investigation, Writing

60 - Review & Editing, Supervision, Visualization, Project Administration **NYW:** Methodology,

61 Investigation, Writing - Review & Editing, Visualization **JMG:** Conceptualization,

62 Methodology, Investigation, Writing - Original Draft, Writing - Review & Editing, Supervision,

63 Project Administration

64

65 **ABSTRACT**

66 **Background:** Increasing numbers of injured patients taking dabigatran are presenting to trauma
67 centers raising an important clinical question: Does reversal with idarucizumab outweigh
68 potential bleeding risks associated with dabigatran? The purpose of this study was to describe the
69 prevalence of idarucizumab administration in trauma patients and compare outcomes for those
70 who received reversal to those who did not.

71 **Methods:** This retrospective cohort study included trauma inpatients ≥ 18 years on preinjury
72 dabigatran. Patients were sourced from the registries of Level I–IV trauma centers with an arrival
73 date 1/2017–12/2021. Preinjury dabigatran therapy and idarucizumab administration were
74 confirmed via EMR chart review. Patients on preinjury dabigatran were grouped according to
75 administration status of idarucizumab.

76 **Results:** 942 trauma patients on preinjury dabigatran (49.7% male; mean GCS:15; ≥ 70 years:
77 85.7%) were included, with 10.8% patients reversed with idarucizumab. No statistically
78 significant differences were found for preinjury dabigatran dose ($p=0.703$), age ($p=0.494$), blunt
79 injury type ($p=0.070$), or mechanism of injury ($p=0.248$). Those reversed with idarucizumab had
80 a greater median head AIS score (3 vs 2; $p<0.001$), higher proportion full trauma activations
81 (16.7 vs 8.7%; $p=0.019$), higher median ISS (10 vs 9; $p<0.001$), were more likely to have a GCS
82 3–8 (4.9% vs 0.8%; $p=0.006$), and had increased rates of blood transfusion (4.9% vs 1.3%;
83 $p=0.022$), ventilator use (10.8% vs 4.7%, $p=0.009$), and mortality (expired+hospice) (10.8% vs
84 4.9%; $p=0.021$). There was no difference between groups for thromboembolic events (1.0% vs
85 0.7%; $p=0.553$), hospital LOS (3 vs 4 days; $p=0.147$), or ICU LOS (3 vs 3 days; $p=0.714$).

86 **Conclusions:** In this large, retrospective cohort study of trauma patients, only 10.8% had
87 reversal with idarucizumab. Patients reversed were more severely injured, with increased ICU
88 and ventilator use, more transfusions ≤ 24 hours, and had increased mortality compared to those
89 not reversed. There was no difference in thromboembolic events between groups. These findings
90 suggest clinicians may be administering idarucizumab based on injury severity – especially head
91 trauma – regardless of other variables, such as comorbidities. Additional research is needed to
92 determine the optimal role of reversal with idarucizumab vs. other strategies for injured patients
93 on dabigatran.

94

95 **KEYWORDS:** Idarucizumab; Anticoagulant Reversal Agents; Dabigatran; Thromboembolism;
96 Bleeding

97

98 **Clinical Perspective**

99 **What is new?**

- 100 • Trauma patients on preinjury dabigatran reversed with idarucizumab were more severely
101 injured and utilized more hospital resources (including increased intensive care unit
102 length of stay and ventilator days) than those not reversed.
- 103 • There was no difference in thromboembolic events recorded between trauma patients
104 administered idarucizumab compared to those who were not; however, reversal with
105 idarucizumab was associated with increased rates of blood transfusion and total mortality
106 (expired + hospice).

107

108 **What are the clinical implications?**

- 109 • These findings suggest clinicians may be administering idarucizumab to trauma patients
110 based primarily on injury severity, especially head trauma, regardless of other variables,
111 such as comorbidities.
- 112 • A large, prospective randomized study of trauma inpatients on preinjury dabigatran that
113 compares dabigatran reversal with idarucizumab to non-specific reversal agents is
114 warranted to establish appropriate criteria for utilization of idarucizumab.

115

116

117 **NON-STANDARD ABBREVIATIONS AND ACRONYMS:**

118 DOAC: direct oral anticoagulants

119 FDA: Food and Drug Administration

120 DVT: deep vein thrombosis

121 PE: pulmonary embolism

122 TBI: traumatic brain injury

123 NSTEMI: non-ST elevation myocardial infarction

124 ED: emergency department

125 MOI: mechanism of injury

126 ICD-10-CM: International Classification of Diseases, Tenth Revision, Clinical Modification

127 EMR: electronic medical record

128 MAR: medication administration record

129 EDW: electronic data warehouse

130 ICU: intensive care unit

131 LOS: length of stay, reported in days

132 IRB: institutional review board

133 STROBE: Strengthening the Reporting of Observational Studies in Epidemiology

134 ISS: injury severity score

135 IQR: interquartile range

136 GCS: Glasgow Coma Score

137 AIS: abbreviated injury score

138

139 **INTRODUCTION**

140 Warfarin has long been considered the gold standard for anticoagulation for a wide range of
141 conditions. As evidence accumulates on the role of direct oral anticoagulants (DOAC) in the
142 prevention of thrombosis, more patients are transitioning from warfarin to DOAC therapy. From
143 2011 to 2017, prescriptions for DOACs as a proportion of all oral anti-coagulants increased from
144 22.1% to 87.3%, whereas warfarin prescriptions decreased from 77.9% to 12.7%.¹ As expected,
145 with the increase in DOAC prescriptions, there has been an increase in the prevalence of injured
146 patients arriving at hospitals who are on preinjury DOAC therapy, including dabigatran.

147
148 Dabigatran is a DOAC approved by the Food and Drug Administration (FDA) to reduce the risk
149 of stroke and systemic embolism in those with atrial fibrillation, to treat deep venous
150 thromboembolism (DVT) and pulmonary embolism (PE) in patients who have been on a 5 – 10
151 day course of a parenteral anticoagulant, to reduce recurrence of DVT and PE, and for DVT and
152 PE prophylaxis in patients who have recently experienced hip replacement surgery.² Dabigatran
153 is the third most frequently prescribed DOAC– with the majority of patients prescribed the drug
154 being in the geriatric age group.³

155
156 The proportion of individuals aged ≥ 65 years in the US is growing, having increased by one-
157 third between 2010 and 2020,^{4,5} and making up 50.7% of all trauma admissions in 2016.⁶
158 Indications for dabigatran are more prevalent in the geriatric age group (e.g. atrial fibrillation),
159 and as the use of dabigatran and other DOACs has also increased, more trauma patients are
160 presenting on preinjury DOAC therapy. Furthermore, older individuals have an increased
161 tendency to fall, and anticoagulant therapy such as dabigatran, places them at an increased risk of

162 hemorrhage – even life-threatening bleeding – in situations such as traumatic brain injury
163 (TBI).^{2,7} Growth in the geriatric population and increased prescribing of dabigatran places more
164 individuals at risk for bleeding complications from trauma, and underscores the importance of
165 clinical-decision making in the evaluation and management of a trauma patient on preinjury
166 dabigatran, balancing the risks of bleeding against those of thrombo-embolic events.

167
168 Idarucizumab is a human monoclonal antibody fragment approved by the FDA for the reversal of
169 dabigatran, specifically binding to the DOAC to neutralize its anticoagulant effect. Importantly,
170 idarucizumab is FDA approved for use in emergency surgeries or urgent procedures and life-
171 threatening or uncontrolled bleeding.⁸ Regardless of these approved indications, the
172 administration of idarucizumab is widely disputed among emergency clinicians due to potential
173 adverse events, cost, and lack of supporting literature concerning its use in trauma patients.^{9,10}
174 Post-marketing and case reports have indicated idarucizumab administration to potentially be
175 associated with an increased thromboembolic risk, including DVT, PE, atrial thrombus, non-ST
176 elevation myocardial infarction (NSTEMI), and ischemic stroke.¹¹ Despite reports of these
177 events occurring in less than 1% of patients,¹¹ these thromboembolic adverse reactions prompt
178 concern. As trauma patients are inherently in a hypercoagulable state,¹² clinicians are faced with
179 the decision as to whether reversal with idarucizumab in this patient population outweighs the
180 potential bleeding risks associated with dabigatran.

181
182 The purpose of this retrospective cohort study was to describe the prevalence of idarucizumab
183 administration in a large sample of trauma patients from a single, nationwide hospital system and

184 compare the outcomes of trauma inpatients on preinjury dabigatran who received reversal with
185 idarucizumab to those who did not receive idarucizumab.

186

187 **METHODS**

188 **Study sample and data sources**

189 In this retrospective cohort study, trauma patients from a large hospital network were included if
190 they were ≥ 18 years, on pre-injury dabigatran therapy, and presented to the emergency
191 department (ED) between January 1, 2017 and December 31, 2021. Patient demographics
192 including age, sex, race, and injury characteristics (injury type and mechanism) were retrieved
193 from the system-wide trauma registry. Mechanism of injury (MOI) for each patient was
194 identified using International Classification of Diseases, Tenth Revision, Clinical Modification
195 (ICD-10-CM) external cause of injury codes. Preinjury dabigatran use was retrieved from the
196 electronic medical record (EMR), which included patient-reported documentation of home
197 medications in patients' medical history, while idarucizumab dose and administration were
198 sourced from the ED medication administration record (MAR). Preinjury dabigatran therapy and
199 idarucizumab administration were further confirmed via EMR data from the electronic data
200 warehouse (EDW). Each patient record was assessed for dabigatran therapy and idarucizumab
201 administration, identified by both the generic and trade names (Pradaxa[®] and Praxbind[®],
202 respectively) via string search. Only patients taking a preinjury dose of dabigatran 75 mg twice
203 daily or 150 mg twice daily were included; patients who reported preinjury dabigatran 110 mg or
204 dabigatran 220 mg were excluded, as this dose is currently only indicated for prophylaxis of
205 DVT and PE following hip replacement surgery.² Patients with nontraumatic ischemic or
206 hemorrhagic strokes that were present on admission were excluded.

207

208 **Variable definitions**

209 The primary goal of the study was to characterize the administration of the reversal agent
210 idarucizumab among trauma patients on preinjury dabigatran therapy. Patients on preinjury
211 dabigatran were grouped according to whether or not they were administered the dabigatran
212 reversal agent, idarucizumab. Administration of idarucizumab – including dosage and time of
213 dose – was sourced from drug administration data in the EDW using string search on the generic
214 name and trade name of Praxbind[®]. Any inconsistencies in the documentation of idarucizumab
215 administration were reviewed by a clinical staff pharmacist on the study team to confirm dosing
216 records for accuracy.

217

218 Secondary outcomes included patient-related outcomes for trauma patients on preinjury
219 dabigatran who were administered idarucizumab compared to those who were not administered
220 idarucizumab. These patient outcomes included hemorrhagic events, thromboembolic events,
221 discharge disposition, total mortality, and hospital resource utilization. Hemorrhagic events
222 included hemorrhagic stroke or “bleeding”; since this outcome was not consistently captured in
223 the EDW, “bleeding” was defined as the occurrence of a blood transfusion within the first 0 – 4
224 hours or 5 – 24 hours of admission as a proxy variable, given this temporal parameter was
225 consistently documented in the trauma registry. Thromboembolic events included
226 thromboembolic stroke, DVT, or PE. Both hemorrhagic stroke and thromboembolic stroke
227 events were sourced from the EDW using ICD-10-CM diagnosis codes (Supplemental Table 1).
228 “Total mortality” was defined as the proportion of patients who expired as an inpatient, or were
229 discharged to hospice. Therefore, “Total mortality” was the sum of inpatient deaths (“Expired”)

230 and hospice discharges (“Hospice”) as documented in the trauma registry.¹³ Hospital resource
231 utilization information was also extracted from the trauma registry, and included length of stay
232 (LOS, reported in days), intensive care unit (ICU) utilization, ICU LOS, ventilator utilization,
233 and days on a ventilator.

234

235 The R package ‘comorbidity’ was used to compute a van Walraven weighted Elixhauser score.¹⁴
236 Since the specific indication for preinjury dabigatran therapy was not consistently available in
237 the EDW or trauma registry, the EDW was searched for the presence of the comorbidity of
238 interest for which dabigatran therapy is indicated, i.e. atrial fibrillation. History of atrial
239 fibrillation, or the presence of atrial fibrillation on arrival using ICD-10-CM diagnosis codes,
240 was deemed the most likely primary reason for dabigatran therapy (Supplemental Table 1).

241

242 **Statistical analyses**

243 Descriptive analyses comparing trauma patients who were administered idarucizumab to those
244 who did not receive idarucizumab were performed for patient demographics, diagnoses, and
245 outcomes using Pearson χ^2 tests of association for categorical variables, and Wilcoxon Rank Sum
246 tests for continuous variables. Fisher’s exact test was used for categorical outcomes with fewer
247 than ten results in each category. *P* values less than .05 were considered statistically significant.
248 R software version 4.2.2 was used for all analyses.¹⁵ The Institutional Review Board (IRB) of the
249 University of Tennessee Health Science Center waived ethical approval for this work and
250 determined it to be exempt from IRB oversight. The Strengthening the Reporting of
251 Observational Studies in Epidemiology (STROBE) guidelines were utilized in the reporting of

252 this research (Supplemental Table 2).¹⁶ The authors had full access to all data in the study and
253 take responsibility for the integrity of the data and accuracy of the data analysis.

254

255 **RESULTS**

256 **Patient characteristics**

257 There were 500□339 patients in the trauma registry that presented to one of 74 facilities, which
258 included 8 Level I, 35 Level II, 20 Level III, and 11 Level IV trauma centers, between January 1,
259 2017, and December 31, 2021. Only 1177 (0.2%) met the aforementioned study criteria for
260 preinjury dabigatran use. Fifty-two patients admitted to facilities that did not have idarucizumab
261 on formulary during the study period were excluded from the analysis. In addition, admissions
262 that did not meet the inclusion criteria were withdrawn (duplicate trauma identifications = 7;
263 under age 18 = 1; patients on hip replacement 110 mg dabigatran dose = 41; nontraumatic stroke
264 present on arrival = 134). After these exclusions, 942 unique patients remained, with 102
265 (10.8%) who received idarucizumab and 840 (89.2%) who did not (Figure 1).

266

267 The majority of patients were 70 years of age or older (85.7%), with 484 (51.4%) in the 70 – 84
268 age range. There were 474 (50.3%) female patients. The study sample was predominantly White
269 (92.9%), with 18 (1.9%) Black patients and 49 (5.2%) Other races. A higher proportion of Black
270 patients were administered idarucizumab compared to those who did not receive idarucizumab
271 (4.9% vs 1.5%, $P=0.037$). Ninety-one patients received the FDA recommended dosage of 5
272 grams (89.2%), 5 patients received 2.5 grams (4.9%), 2 patients received 10 grams (2.0%), and
273 there was missing dosage administration data for 4 patients (3.9%). There were 795 (84.4%)
274 patients with a documented history of atrial fibrillation, which was identified as a proxy of the
275 indication for their preinjury dabigatran therapy. A statistically significantly larger proportion of

276 patients administered idarucizumab had a full trauma activation on arrival compared to patients
 277 who did not receive the reversal drug (16.7% vs 8.7%, $P=0.019$; Table 1). No statistically
 278 significant differences were found for sex, age, Elixhauser score, transfers in, indication for
 279 dabigatran therapy, or dabigatran dose between patients who were administered idarucizumab
 280 and those who were not (Table 1).

281 **Table 1.** Demographic and Clinical Patient Characteristics

Patient Demographics	Overall N=942	Idarucizumab Grouping		<i>P</i> value*
		Idarucizumab n=102 (10.8%)	No Idarucizumab n=840 (89.2%)	
Female sex, n (%)	474 (50.3%)	47 (46.1%)	427 (50.8%)	.364
Race				.048
White, n (%)	875 (92.9%)	90 (88.2%)	785 (93.5%)	.065
Black, n (%)	18 (1.9%)	5 (4.9%)	13 (1.5%)	.037
Other, n (%)	49 (5.2%)	7 (6.9%)	42 (5.0%)	.475
Age, y, median [IQR]†	81 [74, 87]	80 [74.3, 86.5]	81 [74, 87]	.650
Age group				.494
18-54 years, n (%)	19 (2.0%)	1 (1.0%)	18 (2.1%)	.711
55-69 years, n (%)	116 (12.3%)	11 (10.8%)	105 (12.5%)	.750
70-84 years, n (%)	484 (51.4%)	60 (58.8%)	424 (50.5%)	.117
≥85 years, n (%)	323 (34.3%)	30 (29.4%)	293 (34.9%)	.320
Elixhauser score, median [IQR]†	10 [5, 17]	9 [5, 16.8]	11 [5, 17]	.264
Transfers in, n (%)	186 (19.7%)	20 (19.6%)	166 (19.6%)	.971
Activation type				.010
Full, n (%)	90 (9.6%)	17 (16.7%)	73 (8.7%)	.019
Partial, n (%)	266 (28.2%)	31 (30.4%)	235 (28.0%)	.642
Consult, n (%)	255 (27.1%)	30 (29.4%)	225 (26.8%)	.557
None, n (%)	266 (28.2%)	15 (14.7%)	251 (29.9%)	.001
Unknown/Missing, n (%)	65 (6.9%)	9 (8.8%)	56 (6.7%)	.408
Preinjury dabigatran indication				.791
Atrial fibrillation, n (%)	795 (84.4%)	87 (85.3%)	708 (84.3%)	-
Other, n (%)	147 (15.6%)	15 (14.7%)	132 (15.7%)	-
Preinjury dabigatran dose				.703
75 mg BID†, n (%)	262 (27.8%)	30 (29.4%)	232 (27.6%)	-
150 mg BID†, n (%)	680 (72.2%)	72 (70.6%)	608 (72.4%)	-

282 *All comparisons between idarucizumab administration and no idarucizumab administration were
 283 significant at $P < .05$.

284 †Abbreviations: IQR=interquartile range; BID=bis in die (twice a day).

285

286 **Injury description**

287 Falls were the most common MOI (85.2%), with 639 (67.8%) patients presenting for same-level
288 falls, and 164 (17.4%) categorized in the trauma registry as “other falls” (Table 2). The MOI was
289 not statistically significantly different between those who received idarucizumab and those who
290 did not ($P=0.248$). Overall, median injury severity score (ISS) was 9 [interquartile range (IQR)
291 4-10], but the group administered idarucizumab had a statistically significantly higher median
292 score than those who did not (10 [IQR 8 – 17] vs 9 [IQR 4 – 9]; $P<0.001$). Similarly, when ISS
293 was categorized, there was a greater proportion of patients in the more severely injured “16 – 24”
294 and “ ≥ 25 ” ISS groupings for those who were administered idarucizumab compared to patients
295 who did not receive the drug (29.4% vs 3.8%, and 10.8% vs 2.1%, respectively; $P<0.001$).
296 Median Glasgow Coma Score (GCS) was 15 [IQR 15 – 15] across the sample, as well as in each
297 group; however, when GCS was examined by category, the idarucizumab group had a
298 statistically significantly higher proportion of patients in the most severe “3 – 8” range, with 5
299 (4.9%) patients compared to 7 (0.8%) patients who did not receive idarucizumab ($P<0.001$).
300 Furthermore, patients administered idarucizumab were more likely to have a higher head
301 abbreviated injury score (AIS), with the median being 3 [IQR 3 – 4], compared to those who
302 were not administered idarucizumab (2 [IQR 2 – 3]). All injury characteristics are reported in
303 Table 2.

304

305

306

307

308

309 **Table 2.** Injury Patterns of Patients Administered Idarucizumab Compared to Patients Who Did
 310 Not Receive Idarucizumab

	Overall N=942	Idarucizumab Grouping		P value*
		Idarucizumab n=102 (10.8%)	No Idarucizumab n=840 (89.2%)	
Injury type				.070
Blunt, n (%)	924 (98.1%)	98 (96.1%)	826 (98.3%)	.121
Penetrating, n (%)	8 (0.8%)	3 (2.9%)	5 (0.6%)	.046
Other/unspecified, n (%)	3 (0.3%)	0 (0.0%)	3 (0.4%)	1.000
Missing injury type, n (%)	7 (0.7%)	1 (1.0%)	6 (0.7%)	.553
MOI				.248
Same level fall, n (%)	639 (67.8%)	63 (61.8%)	576 (68.6%)	.178
Other fall, n (%)	164 (17.4%)	21 (20.6%)	143 (17.0%)	.406
MVC, n (%)	59 (6.3%)	6 (5.9%)	53 (6.3%)	1.000
Motorcycle, n (%)	9 (1%)	1 (1%)	8 (1%)	1.000
Pedestrian, n (%)	12 (1.3%)	3 (2.9%)	9 (1.1%)	.132
Pedal cyclist, n (%)	10 (1.1%)	2 (2.0%)	8 (1.0%)	.296
Assault, n (%)	7 (0.7%)	2 (2.0%)	5 (0.6%)	.170
Other, n (%)	39 (4.1%)	4 (3.9%)	35 (4.2%)	1.000
Missing MOI, n (%)	3 (0.3%)	0 (0.0%)	3 (0.4%)	1.000
ISS, median [IQR]†	9 [4, 10]	10 [8, 17]	9[4, 9]	<.001
ISS 1 – 8, n (%)	426 (45.2%)	27 (26.5%)	399 (47.5%)	<.001
ISS 9 – 15, n (%)	422 (44.8%)	33 (32.4%)	389 (46.3%)	.008
ISS 16 – 24, n (%)	62 (6.6%)	30 (29.4%)	32 (3.8%)	<.001
ISS ≥25, n (%)	29 (3.1%)	11 (10.8%)	18 (2.1%)	<.001
Missing, n (%)	3 (0.3%)	1 (1.0%)	2 (0.2%)	.291
AIS				
Head, median [IQR]†	3 [2, 3]	3 [3, 4]	2 [2, 3]	<.001
Face, median [IQR]†	3 [2, 3]	2.5 [2, 3]	3 [2, 3]	.639
Chest, median [IQR]†	2 [1, 2]	2 [1, 2]	2 [1, 2]	.879
Abdomen, median [IQR]†	3 [2, 3]	3 [2, 3]	3 [2, 3]	.613
Extremities, median [IQR]†	2 [2, 2]	2 [2, 2]	2 [2, 2]	.790
External, median [IQR]†	1 [1, 1]	1 [1, 1]	1 [1, 1]	.268
GCS, median [IQR]†	15 [15, 15]	15 [15, 15]	15 [15, 15]	<.001
GCS 3 – 8, n (%)	12 (1.3%)	5 (4.9%)	7 (0.8%)	.006
GCS 9 – 12, n (%)	16 (1.7%)	4 (3.9%)	12 (1.4%)	.085
GCS 13 – 15, n (%)	859 (91.2%)	91 (89.2%)	768 (91.4%)	.459
Missing GCS, n (%)	55 (5.8%)	2 (2.0%)	53 (6.3%)	.113

311 *All comparisons between idarucizumab administration and no idarucizumab administration were
 312 significant at $P < .05$.

313 †Abbreviations: MOI=Mechanism of Injury; MVC=motor vehicle collision; ISS=injury severity score;
 314 IQR=interquartile range; AIS=Abbreviated injury score; GCS=Glasgow Coma Score.

315

316 **Outcomes**

317 In the overall sample, there were 16 (1.7%) patients who received transfusions, indicating
 318 significant hemorrhage. Patients administered idarucizumab were more likely to experience
 319 bleeding that required transfusion compared to those who did not receive idarucizumab (4.9% vs
 320 1.3%, respectively; $P=0.022$; Table 3).

321 **Table 3.** Outcomes of Patients Administered Idarucizumab Compared to Patients Who Did Not
 322 Receive Idarucizumab

	Overall	Idarucizumab Grouping		<i>P</i> value*
		Idarucizumab	No Idarucizumab	
		N=942	n=102 (10.8%)	
Hemorrhagic event, n (%)	16 (1.7%)	5 (4.9%)	11 (1.3%)	.022
Hemorrhagic stroke, n (%)	0	0	0	–
Transfusion within 24 hours, n (%)	16 (1.7%)	5 (4.9%)	11 (1.3%)	.022
0 – 4 hours, n (%)	16 (1.7%)	5 (4.9%)	11 (1.3%)	.022
5 – 24 hours, n (%)	4 (0.4%)	2 (2.0%)	2 (0.2%)	.006
Thromboembolic event, n (%)	7 (0.7%)	1 (1.0%)	6 (0.7%)	.553
Thromboembolic stroke, n (%)	4 (0.4%)	1 (1.0%)	3 (0.4%)	.368
Deep Vein thrombosis, n (%)	3 (0.3%)	0	3 (0.4%)	1.000
Pulmonary embolism, n (%)	1 (0.1%)	0	1 (0.1%)	1.000
ICU use, n (%)	315 (33.4%)	78 (76.5%)	237 (28.2%)	<.001
ICU LOS, days, median [IQR]†	3 [2,5]	3 [2, 5]	3 [2, 5]	.714
Ventilator use, n (%)	52 (5.5%)	11 (10.8%)	41 (4.9%)	.021
Ventilator days, median [IQR]†	3 [2, 7]	4 [2, 10]	3 [2, 6]	.352
Hospital LOS, days, median [IQR]†	4 [2, 6]	3 [2, 5]	4 [2, 6]	.147
Withdrawal of care	13 (1.4%)	4 (3.9%)	9 (1.1%)	.043
Discharge disposition				<.001
Expired, n (%)	30 (3.2%)	5 (4.9%)	25 (3.0%)	.362
Hospice, n (%)	20 (2.1%)	6 (5.9%)	14 (1.7%)	.015
Home, n (%)	346 (36.7%)	42 (41.2%)	304 (36.2%)	.329
Nursing facility, n (%)	332 (35.2%)	24 (23.5%)	308 (36.7%)	.009
Other, n (%)	214 (22.7%)	25 (24.5%)	189 (22.5%)	.619
Total Mortality (Expired + Hospice), n (%)	50 (5.3%)	11 (10.8%)	39 (4.6%)	.017

323 *All comparisons between idarucizumab administration and no idarucizumab administration were
 324 significant at $P < .05$.

325 †Abbreviations: ICU=intensive care unit; LOS=length of stay; IQR=interquartile range.

326

327 A total of 7 (0.7%) patients had a thromboembolic event reported. There were 4 (0.4%) patients
328 who had a thromboembolic stroke, 3 (0.3%) who had a clinically detectable DVT, and 1 (0.1%)
329 who had a PE. The four patients who had either a clinically detectable DVT or PE were in the
330 group that did not receive idarucizumab, but there was no statistically significant difference
331 between the two groups for thromboembolic events of any kind (Table 3).

332
333 In terms of hospital resource utilization, 76.5% of those administered idarucizumab had any LOS
334 in the ICU, while 28.2% of those not administered idarucizumab had any LOS in the ICU
335 ($P<0.001$). Despite this difference, patients had a similar median ICU LOS of 3 [IQR 2 – 5] days
336 both across the sample and within groups. Ventilator use was also more prevalent in those
337 administered idarucizumab (11 patients, 10.8%), compared to 41 (4.9%) patients for those who
338 did not receive idarucizumab ($P<0.021$), though the number of days on a ventilator was not
339 statistically significantly different between the two groups, with an overall median of 3 [IQR 2 –
340 7] days.

341
342 The total mortality, which was defined as the sum of patients who expired in the inpatient setting
343 and those who were discharged to hospice, was found to be statistically significantly different
344 between the two groups, with a higher proportion among those administered idarucizumab
345 compared to those who were not given the drug (10.8% vs 4.6%, $P=0.017$). This statistically
346 significant difference in the proportion of total mortality was most affected by those discharged
347 to hospice. In patients who received idarucizumab, 5.9% were discharged to hospice, while 1.7%
348 were discharged to hospice in the patient group who did not receive idarucizumab ($P=0.015$).
349 The number of patients who expired in the inpatient setting was not statistically significantly

350 different between the groups, 5 (4.9%) in the patient group who received idarucizumab
351 compared to 25 (3.0%) in patients who did not receive idarucizumab ($P=0.362$; Table 3).

352

353 **DISCUSSION**

354 This retrospective cohort study was conducted to characterize the prevalence of idarucizumab
355 administration in trauma patients on preinjury dabigatran therapy. In the analysis of 942 trauma
356 patients on preinjury dabigatran therapy (0.2% of all trauma patients seen) from 74 level I–IV
357 trauma centers and non-trauma centers, 102 (10.8%) were administered idarucizumab for the
358 reversal of dabigatran. Patients who were administered idarucizumab were found to be more
359 severely injured with a higher ISS and had an increased proportion of total mortality. Compared
360 to those who did not receive the reversal drug, idarucizumab administration was associated with
361 a higher proportion of full trauma activations, increased ICU and ventilator use, and more
362 transfusions within the first 24 hours of admission. There was not a statistically significant
363 difference between the two groups for the number of individuals who expired in the hospital, but
364 patients who received idarucizumab were more likely to be discharged to hospice, which
365 increased total mortality (expired in-hospital + hospice) in the group that received dabigatran
366 reversal with idarucizumab. There were no statistically significant differences in clinically
367 detectable thromboembolic events – including thromboembolic stroke, DVT, and PE – between
368 those who were administered idarucizumab and those who were not.

369

370 As the numbers of elderly patients continues to increase, comorbidities associated with aging –
371 such as atrial fibrillation¹⁷ – are also on the rise and frequently necessitate the use of
372 anticoagulant medications, including dabigatran.¹⁷⁻¹⁹ Despite the protective anticoagulative

373 properties dabigatran has to offer patients with atrial fibrillation, its use may pose increased
374 bleeding risks following injury. When emergency surgery or urgent procedures are needed, or a
375 patient presents with life-threatening or uncontrolled bleeding, the reversal of dabigatran may be
376 required. Idarucizumab binds to dabigatran with 350 times greater affinity than does thrombin,
377 thereby negating its anticoagulant effect, which is concerning, as studies have shown increased
378 adverse events in elderly patients when dabigatran is reversed with idarucizumab.^{20,21} Similar to
379 other studies regarding the use of idarucizumab in the reversal of dabigatran, the majority of
380 patients who met eligibility criteria in this study were elderly.²²⁻²⁴ Despite the majority of
381 dabigatran reversal with idarucizumab tending to occur in the elderly, this study found there was
382 no association between increasing age and idarucizumab administration among trauma patients.

383
384 Several studies have reported the safety of idarucizumab administration. A retrospective case-
385 control study that included hospitalized patients for dabigatran-associated nontraumatic
386 gastrointestinal bleeding or intracranial bleeding by Singh et al noted there were no significant
387 differences in mortality (odds ratio, 1.39 [95% CI, 0.51–3.45]) or venous thromboembolism
388 (odds ratio, 0.35 [95% CI, 0.08–1.58]) for those who received idarucizumab compared to those
389 who did not receive the reversal drug.²⁵ Similarly, a meta-analysis by Chaudhary et al stated
390 idarucizumab had a “promising safety profile” with 82% anticoagulation reversal and low
391 mortality (11%) and thromboembolic events (5%).²⁴ Chaudhary et al also instill a hint of doubt
392 by stating, “*While the safety data from these landmark trials were promising, head-to-head trials*
393 *have not compared the safety and outcomes of idarucizumab or andexanet alfa (AA) with*
394 *traditional nonspecific reversal agents (FFP, 4F-PCC, or A-PCC).”²⁴ Furthermore, the
395 American College of Gastroenterology-Canadian Association of Gastroenterology Clinical*

396 Guideline recommends against the use of idarucizumab for those with gastrointestinal bleeding
397 due to limited evidence of benefit and the high cost of the drug.²⁶

398

399 In this study, a statistically and clinically significant proportion of patients who received
400 idarucizumab were more likely to be severely injured and have a full trauma activation,
401 compared to those who did not. Patients administered idarucizumab were more likely to have a
402 higher ISS, a higher rate of transfusion, a higher AIS of the head, a lower GCS, and increased
403 ICU and ventilator use. Consistent with these markers of severity and increased risk, they were
404 also more likely to have higher total mortality (expired in hospital + hospice). This statistically
405 significant increased mortality for those who received idarucizumab is more likely related to the
406 patient's injury severity than to the administration of idarucizumab. Interestingly, compared to
407 those who did not receive idarucizumab, patients who were administered the drug were less
408 likely to expire in the hospital, yet the total mortality calculation (expired in hospital+ hospice)
409 indicated a statistically significant increase in total mortality for those administered
410 idarucizumab, suggesting discharge to hospice – and not age itself as reported above – may play
411 a role in this outcome as reported in previous studies of trauma patients.^{27,13}

412

413 Regardless of any hesitancy to utilize the drug, adherence to the idarucizumab FDA
414 recommended dosing appears to be relatively high. There are few large studies concerning
415 idarucizumab dosage compliance. Our study – with 89.2% compliance – was similar to a small
416 study by Mitrovic, et al. that included 68 patients on pre-admission dabigatran.²² They reported
417 94% of patients were administered idarucizumab with the appropriate FDA dosing guidance.

418

419 Idarucizumab administration may place trauma patients at an increased risk of thromboembolic
420 events, not only due to the coagulative drug properties of idarucizumab binding to dabigatran
421 and negating its anticoagulative effects, but also due to the fact that trauma patients present in a
422 hypercoagulable state.²⁸ This study found no statistically significant differences in clinically
423 detectable thromboembolic events between groups. All patients were not actively surveilled for
424 this outcome or evaluated for these potential adverse events following discharge, limiting the
425 conclusion that may be drawn from this finding.

426
427 The clinically important findings reported in this study may be indicative of specific effects of
428 idarucizumab in the trauma patient, as few studies have been conducted strictly in this high-risk
429 population. A small study of 15 trauma patients by Oberladstätter et al found similar results to
430 this study, in which no patients who received idarucizumab experienced clinically detectable
431 thromboembolic events. Conversely, previous studies that included non-trauma patients found
432 idarucizumab administration to be associated with increased clinically detectable
433 thromboembolic events.^{20,29}

434

435 **Limitations**

436 The usual cautions regarding retrospective analysis of administrative datasets are warranted,
437 including the relatively small sample size. Due to the nature of patient-reported preinjury
438 dabigatran use, there is the potential for cognitive bias. Therefore, we could not verify the time
439 of the patients' last dose of dabigatran with certainty. Our dataset was also lacking detailed
440 information concerning the indication for idarucizumab administration, as well as outcomes
441 associated with each idarucizumab dose (eg, the cause of death or whether there was any

442 expansion of intracranial hemorrhages present on admission). Furthermore, initial dabigatran
443 serum concentration values and dabigatran serum concentration values following administration
444 of idarucizumab were not available.

445

446 **Conclusions**

447 This retrospective cohort study in trauma patients found 983 patients (0.2%) from 87 level I–IV
448 trauma centers were on preinjury dabigatran therapy and 102 (10.4%) were reversed with
449 idarucizumab. Patients administered idarucizumab were found to be more severely injured, and
450 had increased ICU and ventilator use, more transfusions within the first 24 hours of admission,
451 and an increased total mortality compared to those who did not receive idarucizumab. There was
452 no statistically significant difference in clinically detectable thromboembolic events between the
453 two groups. These findings suggest clinicians may be administering idarucizumab based
454 primarily on injury severity, especially head trauma, regardless of other variables such as
455 comorbidities. There may be other more clinically appropriate dabigatran reversal agents in
456 trauma, which warrants further investigation. Additional research is needed to determine the
457 optimal role of reversal with idarucizumab vs. other strategies for injured patients on dabigatran.
458

459 **ACKNOWLEDGMENTS, SOURCES OF FUNDING, & DISCLOSURES**

460 **Acknowledgments:** None

461 **Sources of Funding:** None

462 **Disclosures:** None

463

464

465 **SUPPLEMENTAL MATERIAL**

466 Tables S1-S2

467

468

469 **REFERENCES**

- 470 1. Perreault S, de Denus S, White-Guay B, Côté R, Schnitzer ME, Dubé MP, Dorais M,
471 Tardif JC. Oral anticoagulant prescription trends, profile use, and determinants of
472 adherence in patients with atrial fibrillation. *Pharmacotherapy*. 2020;40(1): 40-54.
- 473 2. Pradaxa. Package insert. Boehringer Ingelheim Pharmaceuticals, Inc; 2023.
- 474 3. Simon TG, Schneeweiss S, Singer DE, Sreedhara SK, Lin KJ. Prescribing trends of oral
475 anticoagulants in US patients with cirrhosis and nonvalvular atrial fibrillation. *J Am*
476 *Heart Assoc*. 2023;12(3):e026863.
- 477 4. United States Census Bureau. 65 and older population grows rapidly as baby boomers
478 age. Published June 25, 2020. Accessed December 6, 2023.
479 <https://www.census.gov/newsroom/press-releases/2020/65-older-population-grows.html>
- 480 5. Vespa J. The U.S. joins other countries with large aging populations. United States
481 Census Bureau. Updated October 8, 2019. Accessed December 4, 2023.
482 <https://www.census.gov/library/stories/2018/03/graying-america.html>
- 483 6. Rios-Diaz AJ, Metcalfe D, Olufajo OA, Zogg CK, Yorkgitis B, Singh M, Haider AH,
484 Salim A. Geographic distribution of trauma burden, mortality, and services in the in the
485 United States: does availability correspond to patient need?. *J Am Coll Surg*.
486 2016;223(6):764-773.e2.
- 487 7. Scotti P, Séguin C, Lo BWY, de Guise E, Troquet JM, Marcoux J. Antithrombotic agents
488 and traumatic brain injury in the elderly population: hemorrhage patterns and outcomes. *J*
489 *Neurosurg*. 2019;133(2):1-10.
- 490 8. Praxbind. Package insert. Boehringer Ingelheim Pharmaceuticals, Inc.; 2015.
- 491

- 492 9. Selby R, Geerts W, Ofosu FA, Craven S, Dewar L, Phillips A, Szalai JP.
493 Hypercoagulability after trauma: hemostatic changes and relationship to venous
494 thromboembolism. *Thromb Res*. 2009;124(3):281-287.
- 495 10. Cuker A, Burnett A, Triller D, Crowther M, Ansell J, Van Cott EM, Wirth D, Kaatz
496 S. Reversal of direct oral anticoagulants: guidance from the Anticoagulation Forum. *Am J*
497 *Hematol*. 2019;94(6):697-709.
- 498 11. Idarucizumab. Lexi-Drugs. Lexicomp. UpToDate, Inc.; 2023. Updated May 11, 2023.
499 Accessed May 25, 2023. <https://online.lexi.com>
- 500 12. Moore EE, Moore HB, Kornblith LZ, Neal MD, Hoffman M, Mutch NJ, Schochl H, Hunt
501 BJ, Sauaia A. Trauma-induced coagulopathy. *Nat Rev Dis Primers*. 2021;7(1):30.
- 502 13. Fakhry SM, Shen Y, Wyse RJ, Garland JM, Watts DD. Variation in hospice use among
503 trauma centers may impact analysis of geriatric trauma outcomes: an analysis of
504 1,961,228 Centers for Medicare and Medicaid Services hospitalizations from 2,317
505 facilities. *J Trauma Acute Care Surg*. 2023;94(4):554-561.
- 506 14. van Walraven C, Austin PC, Jennings A, Quan H, Forster AJ. A modification of the
507 Elixhauser comorbidity measures into a point system for hospital death using
508 administrative data. *Med Care*. 2009;47(6):626-633.
- 509 15. R: A language and environment for statistical computing. R foundation for statistical
510 computing program. Vienna, Austria: R Core Team, 2021. <https://www.R-project.org/>.
511 Accessed August 27, 2023.
- 512 16. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, and
513 STROBE Initiative. The Strengthening the Reporting of Observational Studies in

- 514 Epidemiology (STROBE) statement: guidelines for reporting observational studies.
515 *Epidemiology*. 2007;18(6):800-804.
- 516 17. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE, GO AS,
517 Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults:
518 national implications for rhythm management and stroke prevention: the
519 AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.
520 *JAMA*. 2001;285(18):2370-2375.
- 521 18. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward JB,
522 Tsang TSM. Secular trends in incidence of atrial fibrillation in Olmsted County,
523 Minnesota, 1980 to 2000, and implications on the projections for future prevalence.
524 *Circulation*. 2006;114(2):119-125.
- 525 19. Barnes GD, Lucas E, Alexander GC, Goldberger ZD. National trends in ambulatory oral
526 anticoagulant use. *Am J Med*. 2015;128(12):1300-5.e2.
- 527 20. van der Wall SJ, van Rein N, van den Bemt B, Kruip MJHA, Meijer K, Te Boome LCJ,
528 Simmers TA, Alings AMW, Tieleman R, Klok FA, et al. Performance of idarucizumab as
529 antidote of dabigatran in daily clinical practice. *Europace*. 2019;21(3):414-420.
- 530 21. Rodrigues AO, David C, Ferreira JJ, Pinto FJ, Costa J, Caldeira D. The incidence of
531 thrombotic events with idarucizumab and andexanet alfa: a systematic review and meta-
532 analysis. *Thromb Res*. 2020;196:291-296.
- 533 22. Mitrovic D, van Elp M, Visser L, van Rein N, van den Bemt P, van Hulst M, Dreijer A,
534 Lameijer H, Veeger N, Meijer K, et al. Adherence to protocols for the use of reversal
535 agents in patients treated with direct oral anticoagulants. *Curr Med Res*
536 *Opin*. 2023;39(6):865-871.

- 537 23. da Luz LT, Marchand M, Nascimento B, Tien H, Nathens A, Shah P. Efficacy and safety
538 of the drugs used to reverse direct oral anticoagulants: a systematic review and meta-
539 analysis. *Transfusion*. 2017;57(7):1834.
- 540 24. Chaudhary R, Singh A, Chaudhary R, Bashline M, Houghton DE, Rabinstein A, Adamski
541 J, Amdt R, Ou NN, Rudis MI, et al. Evaluation of direct oral anticoagulant reversal
542 agents in intracranial hemorrhage: a systematic review and meta-analysis. *JAMA Netw*
543 *Open*. 2022;5(11):e2240145.
- 544 25. Singh S, Nautiyal A, Belk KW. Real world outcomes associated with idarucizumab:
545 population-based retrospective cohort study. *Am J Cardiovasc Drugs*. 2020;20(2):161-
546 168.
- 547 26. Abraham NS, Barkun AN, Sauer BG, Douketis J, Laine L, Noseworthy PA, Telford JJ,
548 Leontiadis GI. American College of Gastroenterology-Canadian Association of
549 Gastroenterology Clinical Practice Guideline: Management of Anticoagulants and
550 Antiplatelets During Acute Gastrointestinal Bleeding and the Periendoscopic Period. *Am*
551 *J Gastroenterol*. 2022;117(4):542-558.
- 552 27. Kozar RA, Holcomb JB, Xiong W, Nathens AB. Are all deaths recorded equally? The
553 impact of hospice care on risk-adjusted mortality. *J Trauma Acute Care Surg*.
554 2014;76(3):634-9.
- 555 28. Sloos PH, Maas MAW, Hollmann MW, Juffermans NP, Kleinveld DJB. The effect of
556 shock duration on trauma-induced coagulopathy in a murine model. *Intensive Care Med*
557 *Exp*. 2022;10(1):1.
- 558 29. Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal—full
559 cohort analysis. *N Engl J Med*. 2017;377(5):431-441.

560 **SUPPLEMENTAL FILES**

561 Supplemental files are intended for publication as an online data supplement.

Figure 1. CONSORT diagram for the Comparison of Administered Idarucizumab Study Sample Derivation

